STERIS plc (STE) — ESG & Values Scores

Environment story

STERIS faces material environmental risks centered on EO sterilization operations, regulatory tightening, and incomplete Scope 3 disclosure. The company has settled $48.2M in Illinois litigation related to EO facility emissions and acknowledges EPA classification of EO as carcinogenic (2016). No disclosed net-zero target year or Scope 1/2/3 emissions quantification appears in filings. Company emphasizes 'technology-neutral' sterilization but derives significant revenue from EO contract sterilization without disclosed decarbonization pathway. Risk factors cite evolving EU/UK sustainability reporting requirements (CSRD, ESRS) and potential operational restrictions from EO regulation as material concerns. No disclosed renewable energy percentage or capital investments in physical decarbonization infrastructure identified.

Criticisms on file

Illinois EO Sterilization Litigation Settlement
Source: STE_10K.txt, Risk Factors section & MD&A; binding settlement agreements entered March 3, 2025 and October 29, 2025 totaling ~$48.2M to resolve personal injury claims related to EO exposure in Cook County, Illinois Circuit Court.
EO Sterilization Regulatory Risk & Facility Closures
Source: STE_10K.txt, Risk Factors; EPA determination (2016) that EO is carcinogenic; company notes 'announcements of temporary or permanent closure of EO sterilization facilities operated by others have been associated with state and/or local regulatory or other legal action related to EO emissions.'
Scope 3 Emissions Undisclosed & Rising Operational Risk
Source: STE_10K.txt, MD&A & Risk Factors; no quantified Scope 3 emissions reported; EO operations represent 'significant' portion of AST segment revenue ($1,138.5M in FY2026), but company does not disclose product-use or supply-chain carbon footprint.
Greenwashing Risk & ESG Controversy Exposure
Source: STE_10K.txt, Risk Factors section explicitly cites 'concerns about or allegations of greenwashing' and states 'failure, or perceived failure, by us to achieve our goals...could result in reputational harm or advocacy group campaigns or legal and regulatory proceedings.'

Disclosed initiatives

EO Emissions Compliance & Reduction Measures

Company states AST operations 'have taken and will continue to take measures to comply with all applicable emissions regulations and to reduce emissions' but provides no quantified reduction targets, timelines, or methodology.

Defensive posture; no proactive decarbonization strategy disclosed.
Engagement with Regulatory Requirements (CSRD/ESRS)

Company acknowledges EU Corporate Sustainability Reporting Directive (CSRD) and European Sustainability Reporting Standards (ESRS) amendments (effective 2027 transposition), noting compliance complexity and cost burden.

Reactive compliance only; indicates potential future reporting improvements but no current emissions reduction commitments.

Social story

STERIS reports limited diversity and pay-equity disclosure. No CEO-to-worker pay ratio, executive/board gender composition, or formal DEI program details provided in 10-K. Company cites labor cost inflation and increased compensation expenses but does not disclose union presence, bargaining status, or labor relations controversies. Supply-chain human-rights audits not disclosed; no cobalt, lithium, or conflict-mineral policies mentioned despite AST segment's reliance on cobalt-60 (noted as single-sourced in certain regions). Turnover rates not disclosed. Company emphasizes recruitment and retention challenges but provides no demographic breakdown or DEI commitments.

Criticisms on file

Supply-Chain Material Risk: Cobalt-60 Single-Sourcing
Source: STE_10K.txt, Risk Factors; company notes cobalt-60 is 'single-sourced in certain regions of the world' and acknowledges 'limited number of suppliers' with potential for 'supply shortages or unavailability or increasing prices'; no human-rights audit or conflict-mineral policy disclosed.
Labor Cost Inflation & Compensation Pressures
Source: STE_10K.txt, MD&A; SG&A expenses increased 5.5% in FY2026, 'primarily attributable to increased compensation and benefit costs' and AST segment experienced 'increased labor inflation costs.'
Restructuring & Workforce Reductions
Source: STE_10K.txt, MD&A; May 2024 restructuring plan resulted in elimination of approximately 300 positions; $41.4M in severance costs incurred in FY2025.

Disclosed initiatives

Recruitment and Retention Focus

Company states 'continued success depends, in part, on our ability to hire and retain highly qualified people' and acknowledges labor challenges in both domestic and international markets.

Acknowledges challenge; no proactive DEI or wage-equity program disclosed.
Compliance with Employment Laws

Risk factor notes company is subject to 'employment discrimination' litigation and compliance matters, but no formal EEO-1 disclosure, civil-rights audit, or supplier-diversity program mentioned.

Reactive compliance posture; no affirmative DEI strategy evident.

Governance story

STERIS is organized as a public limited company under Irish law with a dual structure (STERIS plc as parent holding company with U.S. subsidiaries STERIS Corporation and STERIS Limited issuing debt through FinCo). Board independence percentage not disclosed in 10-K. No evidence of dual-class super-majority voting structure identified, but Irish incorporation creates potential tax-treaty and regulatory complexity. Company discloses lobbying exposure related to tariffs, trade policy, and tax reform (OBBBA, GloBE rules, BEPS) but does not quantify annual lobbying spend or separately disclose climate/environmental deregulation lobbying. No SEC consent decrees, antitrust proceedings, or major privacy fines disclosed in current filing; however, significant product-liability and regulatory risks noted (EO litigation, FDA recalls). Credit ratings: BBB (S&P), Baa2 (Moody's), BBB (Fitch).

Criticisms on file

EO Sterilization Litigation & Regulatory Exposure
Source: STE_10K.txt, Risk Factors & MD&A; $48.2M settlement (March/October 2025) with plaintiffs' counsel in Illinois Cook County Circuit Court for personal injury claims related to EO exposure; company acknowledges 'outcome of trials before juries...can be highly unpredictable' and notes insurance may not fully cover future liabilities.
Product Liability & Regulatory Recall Risk
Source: STE_10K.txt, Risk Factors; company faces 'inherent business risk of exposure to product liability claims' and acknowledges FDA can 'require product recalls or impose restrictions'; notes risk of 'warning letters, fines, civil penalties, criminal penalties, loss of tax benefits, injunctions, product seizure, recalls, suspensions or restrictions.'
Antitrust & Trade Policy Lobbying Exposure
Source: STE_10K.txt, Risk Factors; company extensively discloses exposure to tariff uncertainty, USMCA renegotiation risk, and trade-policy volatility; acknowledges 'administrations in the U.S. and other countries continue to announce plans to implement or increase tariffs' and impact on supply-chain costs, but does not disclose specific lobbying spend or positions on deregulation.
Tax Position Uncertainty & IRS Challenge Risk
Source: STE_10K.txt, Risk Factors; company organized under Irish law and faces risk of IRS challenge to its Irish tax residency status; notes 'if proposals are adopted that...limit our ability as an Irish company to take advantage of tax treaties with the U.S., we could be subject to increased taxation and/or potentially significant expense.'
Cybersecurity & Data Privacy Risk
Source: STE_10K.txt, Risk Factors; company acknowledges prior cybersecurity 'attacks and security breaches' (though none material to date); cites GDPR fines risk (up to 4% of global revenue) and evolving AI regulation (EU AI Act) as material compliance burdens.

Disclosed initiatives

Tax Compliance & Treaty Optimization

Company actively manages OECD GloBE/Pillar Two, BEPS MLI, and U.S. tax-treaty positioning; anticipates compliance with OBBBA (U.S. tax reform, July 2025) and GloBE rules in EU jurisdictions. Expects no material impact on FY2026 effective tax rate.

Proactive tax governance; no direct ESG benefit but reduces regulatory risk.
Credit Facility Renewal & Debt Management

Renewed $1.1B Revolving Credit Facility in October 2024 (5-year term); maintained investment-grade credit ratings (BBB/Baa2/BBB); debt-to-total-capital ratio: 21.3% at March 31, 2026, down from 23.6% prior year.

Strong liquidity management; demonstrates financial discipline.
Risk Management & Internal Controls

Company cites compliance with FDA, FCPA, U.K. Bribery Act, and various international regulations; maintains product liability and cyber insurance.

Standard governance practice; no advanced ESG integration disclosed.

These are Missionomics' own editorial scores — directional signals built from disclosed facts under a published method, not certifications or definitive ratings of STERIS plc. Coverage and confidence vary by data point, and figures can lag real-world changes. Read the full Methodology for sourcing, scoring, and correction details — or open STERIS plc in the app for interactive charts and portfolio building.

More in Healthcare

Eli Lilly and Company (LLY) Johnson & Johnson (JNJ) AbbVie Inc. (ABBV) UnitedHealth Group Incorporated (UNH) Merck & Co., Inc. (MRK) Thermo Fisher Scientific Inc. (TMO)